Adverse Events and Drug Resistance in Critically Ill Patients Treated with Colistimethate Sodium: A Review of the Literature
Victor Hugo Ahumada Topete,Kevin Jesus de Dios Sanchez,Gustavo Alejandro Casas Aparicio,Graciela Hernandez Silva,Cesar Emmanuel Lopez Vejar,Luz Maria Torres Espíndola,Arnoldo Aquino-Galvez,Odalis Rodriguez Ganen,Manuel de Jesus Castillejos Lopez
DOI: https://doi.org/10.2147/IDR.S398930
2023-03-11
Infection and Drug Resistance
Abstract:Victor Hugo Ahumada Topete, 1, &ast Kevin Jesus de Dios Sanchez, 1, &ast Gustavo Alejandro Casas Aparicio, 2 Graciela Hernandez Silva, 2 Cesar Emmanuel Lopez Vejar, 1 Luz Maria Torres Espíndola, 3 Arnoldo Aquino-Galvez, 4 Odalis Rodriguez Ganen, 5 Manuel de Jesus Castillejos Lopez 1 1 Hospital Epidemiology and Infectology Unit, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico; 2 Department of Infectious Disease Research, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico; 3 Laboratory of Pharmacology, National Institute of Pediatrics, Mexico City, Mexico; 4 Molecular Biology Laboratory, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico; 5 Department of Hospital Pharmacy, National Institute of Respiratory Diseases Ismael Cosío Villegas, Mexico City, Mexico &astThese authors contributed equally to this work Correspondence: Manuel de Jesus Castillejos Lopez; Arnoldo Aquino Galvez, Email ; The adverse events related to sodium colistimethate have had variability regarding the prevalence of nephrotoxicity, neurotoxicity, and less frequent respiratory depression. In recent years, its use has been relevant due to the increase of multidrug-resistant bacteria since it is considered the last-line drug, being its main adverse event and reason for discrepancies between authors' nephrotoxicity. The indiscriminate use of antibiotic therapy has generated multiple mechanisms of resistance, the most common being related to Colistin, the bactericidal escape effect. Based on the search criteria, no randomized clinical trials were identified showing safety and efficacy with the use of Colistin, inferring that the application of the appropriate dose is governed by expert opinion and retrospective and prospective observational studies, which confounding factors such as the severity of the patient and the predisposition to develop acute renal failure are constant. In this review, we focus on identifying the mechanism of nephrotoxicity and bacterial resistance, where much remains to be known. Keywords: colistin, colistimethate, nephrotoxicity, neurotoxicity, resistance mechanism, multidrug-resistant gram-negative bacteria, risk factors, high doses, toxicity Polymyxins were described in 1947 1,2 in isolates of Bacillus Polymyxa , subspecies coelestinus koyama . 1,3 Sodium colistimethate (CMS) was discontinued in the 1980s due to adverse events such as nephrotoxicity and neurotoxicity, and the marketing of new drugs with a higher safety profile. The lack of efficacy of the new drugs and the indiscriminate use of antibiotics made it an ideal environment for developing multidrug-resistant gram-negative bacilli (BGN-MDR), making their reintroduction feasible two decades later. 2,4 These drugs are cyclic polypeptides whose primary mechanism alters the permeability of the lipopolysaccharide wall of gram-negative bacteria. In the literature, alternative mechanisms are described as the vesicle–vesicle contact route causing exchange and loss of phospholipids and the route of death by hydroxyl radical, given by the reaction of Fenton (hydrogen peroxide oxidizes ferrous iron in serum iron). This reaction generates oxidative damage leading to cell death. 4,5 Its antimicrobial spectrum comprises; A cinetobacter baumannii, Pseudomonas aeruginosa, and K. pneumoniae , having no activity against gram-positive bacteria since it does not bind favorably to lipoteichoic acid. 6 Its use should be reserved as a last-line drug when you have an infection with the bacteria mentioned above and under certain conditions as empirical treatment. 7 We investigate the landscape of nephrotoxicity in the last decade and describe the various resistance mechanisms reported. Until now, it has been considered the last available antibiotic therapy against multi-resistant bacteria. However, during the COVID-19 pandemic, the use of colistin increased due to a lack of evidence of a standardized treatment, resulting in greater antibiotic resistance. Starting from this point, this review will allow more information about renal deterioration and resistance mechanisms associated with this drug in multiple studies. 8 In one of the largest cohorts conducted before the period of his detention by Koch 9 in 1970, evaluated 317 patients using CMS, 63 (20.1%) developed acute kidney injury, while the development of neurological symptoms was in 23 (7.2%) of 317, being one of the Falagas hypotheses 10 that the increase in nephrotoxicity at that time was due to the use of CMS -Abstract Truncated-
pharmacology & pharmacy,infectious diseases